SecBot SecBot
SECBOTREPLAY Home › Report › PHAT

PHAT · Phathom Pharmaceuticals announced the presentation of 31…

Phathom Pharmaceuticals · PRESS-RELEASE filed May 20, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed May 20, 2026 at 08:00 ET

Phathom Pharmaceuticals announced the presentation of 31 vonoprazan-related abstracts at DDW 2026, including a Phathom-sponsored analysis from the Phase 3 pHalcon-NERD-301 study recognized as a Poster of Distinction. The data covers GERD, H. pylori eradication, long-term safety, and post-endoscopic care, but no new regulatory actions or financial guidance were provided.

  • 31 vonoprazan-related abstracts presented at DDW 2026, including 28 independent investigator-initiated studies
  • Phathom-sponsored analysis from Phase 3 pHalcon-NERD-301 study recognized as Poster of Distinction
  • Data covers GERD, H. pylori eradication, long-term safety, and post-endoscopic submucosal dissection use
  • No new FDA decisions, label expansions, or financial updates announced

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access